Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (anti‑PD1/anti‑CTLA4) plus azacitidine and venetoclax in elderly, unfit, and relapsed/refractory AML
ChiCTR2600119729Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of QL1706 in acute myeloid leukemia (AML) (3 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Composite Complete Remission Rate and Recommended Phase II Dose. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600119729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119729.